TY - JOUR
T1 - Characterization and comparison of GITR expression in solid tumors
AU - Vence, Luis
AU - Bucktrout, Samantha L.
AU - Curbelo, Irina Fernandez
AU - Blando, Jorge
AU - Smith, Bevin M.
AU - Mahne, Ashley E.
AU - Lin, John C.
AU - Park, Terrence
AU - Pascua, Edward
AU - Sai, Tao
AU - Chaparro-Riggers, Javier
AU - Subudhi, Sumit K.
AU - Scutti, Jorge B.
AU - Higa, Maria G.
AU - Zhao, Hao
AU - Yadav, Shalini S.
AU - Maitra, Anirban
AU - Wistuba, Ignacio I.
AU - Allison, James P.
AU - Sharma, Padmanee
N1 - Funding Information:
This study was supported by Pfizer Inc.
Publisher Copyright:
© 2019 American Association for Cancer Research.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Purpose: Determine the differential effect of a FcgR-binding, mIgG2a anti-GITR antibody in mouse tumor models, and characterize the tumor microenvironment for the frequency of GITR expression in T-cell subsets from seven different human solid tumors. Experimental Design: For mouse experiments, wild-type C57BL/6 mice were subcutaneously injected with MC38 cells or B16 cells, and BALB/c mice were injected with CT26 cells. Mice were treated with the anti-mouse GITR agonist antibody 21B6, and tumor burden and survival were monitored. GITR expression was evaluated at the single-cell level using flow cytometry (FC). A total of 213 samples were evaluated for GITR expression by IHC, 63 by FC, and 170 by both in seven human solid tumors: Advanced hepatocellular carcinoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, pancreatic carcinoma, head and neck carcinoma, melanoma, and ovarian carcinoma. Results: The therapeutic benefit of 21B6 was greatest in CT26 followed by MC38, and was least in the B16 tumor model. The frequency of CD8 T cells and effector CD4 T cells within the immune infiltrate correlated with response to treatment with GITR antibody. Analysis of clinical tumor samples showed that NSCLC, renal cell carcinoma, and melanoma had the highest proportions of GITR-expressing cells and highest per-cell density of GITR expression on CD4+ Foxp3+ T regulatory cells. IHC and FC data showed similar trends with a good correlation between both techniques. Conclusions:Humantumor data suggest that NSCLC, renal cell carcinoma, and melanoma should be the tumor subtypes prioritized for anti-GITR therapy development.
AB - Purpose: Determine the differential effect of a FcgR-binding, mIgG2a anti-GITR antibody in mouse tumor models, and characterize the tumor microenvironment for the frequency of GITR expression in T-cell subsets from seven different human solid tumors. Experimental Design: For mouse experiments, wild-type C57BL/6 mice were subcutaneously injected with MC38 cells or B16 cells, and BALB/c mice were injected with CT26 cells. Mice were treated with the anti-mouse GITR agonist antibody 21B6, and tumor burden and survival were monitored. GITR expression was evaluated at the single-cell level using flow cytometry (FC). A total of 213 samples were evaluated for GITR expression by IHC, 63 by FC, and 170 by both in seven human solid tumors: Advanced hepatocellular carcinoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, pancreatic carcinoma, head and neck carcinoma, melanoma, and ovarian carcinoma. Results: The therapeutic benefit of 21B6 was greatest in CT26 followed by MC38, and was least in the B16 tumor model. The frequency of CD8 T cells and effector CD4 T cells within the immune infiltrate correlated with response to treatment with GITR antibody. Analysis of clinical tumor samples showed that NSCLC, renal cell carcinoma, and melanoma had the highest proportions of GITR-expressing cells and highest per-cell density of GITR expression on CD4+ Foxp3+ T regulatory cells. IHC and FC data showed similar trends with a good correlation between both techniques. Conclusions:Humantumor data suggest that NSCLC, renal cell carcinoma, and melanoma should be the tumor subtypes prioritized for anti-GITR therapy development.
UR - http://www.scopus.com/inward/record.url?scp=85074377204&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074377204&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-19-0289
DO - 10.1158/1078-0432.CCR-19-0289
M3 - Article
C2 - 31358539
AN - SCOPUS:85074377204
SN - 1078-0432
VL - 25
SP - 6501
EP - 6510
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 21
ER -